PMID- 10811670
OWN - NLM
STAT- MEDLINE
DCOM- 20000615
LR  - 20170210
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 18
IP  - 10
DP  - 2000 May
TI  - Treatment of leptomeningeal metastases evaluated by interphase cytogenetics.
PG  - 2053-8
AB  - PURPOSE: Although cytologic examination of CSF is the primary method for the 
      evaluation of response to therapy for leptomeningeal metastases (LMMs), the 
      procedure's sensitivity decreases throughout the course of protracted therapy. We 
      studied whether this response could be monitored more accurately through the 
      detection of numerical chromosomal aberrations by interphase cytogenetics, using 
      fluorescence in situ hybridization (FISH). PATIENTS AND METHODS: Seven patients 
      treated for LMMs and with a known numerical aberration for chromosome 1 in their 
      pretreatment CSF were included in this study. Up to 16 consecutive CSF samples 
      were analyzed by means of the fluorescence in situ hybridization (FISH) technique 
      for cells with aberrant chromosome 1 content. The results of routine cytology and 
      FISH analyses were compared and were correlated with each patient's neurologic 
      status. RESULTS: Routine cytology detected malignancies in only 24 of the 76 
      samples, all of which were classified as chromosomally abnormal by FISH (except 
      for two samples that could not be evaluated). Moreover, FISH demonstrated 
      aneusomic cells in 32 additional samples, which could therefore be classified as 
      malignant. The FISH results correlated better with patient neurologic status in 
      that more malignant cells were detected in the CSF of neurologically 
      deteriorating patients. CONCLUSION: Using FISH in addition to performing routine 
      cytologic examination of CSF led to a more accurate evaluation of response to 
      treatment in patients treated for LMMs.
FAU - van Oostenbrugge, R J
AU  - van Oostenbrugge RJ
AD  - Departments of Neurology and Pathology, University Hospital of Maastricht, the 
      Netherlands. rvoo@sneu.azm.nl
FAU - Hopman, A H
AU  - Hopman AH
FAU - Arends, J W
AU  - Arends JW
FAU - Ramaekers, F C
AU  - Ramaekers FC
FAU - Twijnstra, A
AU  - Twijnstra A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Antineoplastic Agents)
RN  - 0 (DNA Probes)
SB  - IM
MH  - Antineoplastic Agents/therapeutic use
MH  - *Chromosome Aberrations
MH  - *Chromosomes, Human, Pair 1
MH  - DNA Probes
MH  - Female
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence
MH  - *Interphase
MH  - Male
MH  - Meningeal Neoplasms/cerebrospinal fluid/*drug therapy/*genetics/secondary
MH  - Treatment Outcome
EDAT- 2000/05/16 09:00
MHDA- 2000/06/17 09:00
CRDT- 2000/05/16 09:00
PHST- 2000/05/16 09:00 [pubmed]
PHST- 2000/06/17 09:00 [medline]
PHST- 2000/05/16 09:00 [entrez]
AID - 10.1200/JCO.2000.18.10.2053 [doi]
PST - ppublish
SO  - J Clin Oncol. 2000 May;18(10):2053-8. doi: 10.1200/JCO.2000.18.10.2053.